ATE466084T1 - Hla-a24-restringiertes krebsantigenpeptid - Google Patents

Hla-a24-restringiertes krebsantigenpeptid

Info

Publication number
ATE466084T1
ATE466084T1 AT03736167T AT03736167T ATE466084T1 AT E466084 T1 ATE466084 T1 AT E466084T1 AT 03736167 T AT03736167 T AT 03736167T AT 03736167 T AT03736167 T AT 03736167T AT E466084 T1 ATE466084 T1 AT E466084T1
Authority
AT
Austria
Prior art keywords
hla
cancer antigen
antigen peptide
restricted cancer
restricted
Prior art date
Application number
AT03736167T
Other languages
English (en)
Inventor
Haruo Sugiyama
Masashi Gotoh
Hideo Takasu
Original Assignee
Int Inst Cancer Immunology Inc
Chugai Pharmaceutical Co Ltd
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc, Chugai Pharmaceutical Co Ltd, Dainippon Sumitomo Pharma Co filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE466084T1 publication Critical patent/ATE466084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03736167T 2002-06-12 2003-06-12 Hla-a24-restringiertes krebsantigenpeptid ATE466084T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002171518 2002-06-12
JP2002275572 2002-09-20
PCT/JP2003/007463 WO2003106682A1 (ja) 2002-06-12 2003-06-12 Ｈｌａ−ａ２４拘束性癌抗原ペプチド

Publications (1)

Publication Number Publication Date
ATE466084T1 true ATE466084T1 (de) 2010-05-15

Family

ID=29738372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736167T ATE466084T1 (de) 2002-06-12 2003-06-12 Hla-a24-restringiertes krebsantigenpeptid

Country Status (10)

Country Link
US (2) US7420034B2 (de)
EP (1) EP1536009B1 (de)
JP (1) JP4365784B2 (de)
KR (1) KR101050703B1 (de)
CN (2) CN101113163B (de)
AT (1) ATE466084T1 (de)
AU (1) AU2003242305A1 (de)
CA (1) CA2489227C (de)
DE (1) DE60332355D1 (de)
WO (1) WO2003106682A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103564B1 (de) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
BRPI0208183B8 (pt) * 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
KR101050703B1 (ko) * 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
ES2443582T3 (es) * 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
CN100427502C (zh) * 2005-06-09 2008-10-22 南京大学 抗肿瘤寡肽及其制备方法和应用
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) * 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
EP3117836A1 (de) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verwendungen davon
NZ601175A (en) 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
ATE555212T1 (de) * 2007-03-02 2012-05-15 Biosante Pharmaceuticals Inc Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
WO2008108257A1 (ja) 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
CA2940962C (en) * 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
US10265389B2 (en) * 2009-01-08 2019-04-23 International Institute Of Immunology, Inc. Cancer antigen eEF2
GB2484869A (en) * 2009-08-17 2012-04-25 Univ Tokyo Pharmaceutical composition containing transiently surviving CTL
EP2626418B8 (de) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Verfahren zur aktivierung von t-helferzellen
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
JP6368243B2 (ja) * 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
PT2945647T (pt) * 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
RU2685933C2 (ru) * 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
EP2762156A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation Bandpräparat mit WT1-Peptidkrebsimpfstoff zur transdermalen Verabreichung
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
TWI711633B (zh) * 2014-09-24 2020-12-01 北海道公立大學法人札幌醫科大學 腫瘤抗原胜肽
CN107427581A (zh) 2014-12-25 2017-12-01 株式会社癌免疫研究所 T细胞群的改变方法
EP4130026A1 (de) 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Verfahren und zusammensetzungen zum behandeln von krebs
ES2946188T3 (es) 2016-11-09 2023-07-13 Univ Osaka Procedimiento para modificar una población de linfocitos T
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
EP3858377A4 (de) 2018-09-28 2022-11-30 Sumitomo Pharma Co., Ltd. Injizierbare zusammensetzung
JP7393752B2 (ja) 2018-10-05 2023-12-07 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
CN115605494A (zh) * 2020-05-12 2023-01-13 株式会社Lg化学（Kr） 多聚体t细胞调节多肽及其使用方法
WO2021230247A1 (ja) 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
JPWO2023017836A1 (de) 2021-08-12 2023-02-16

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5779696A (en) * 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
US20030092656A1 (en) * 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
EP1103564B1 (de) * 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028758A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
KR101050703B1 (ko) * 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드

Also Published As

Publication number Publication date
JPWO2003106682A1 (ja) 2005-10-13
US20090099090A1 (en) 2009-04-16
CN101113163B (zh) 2010-10-06
JP4365784B2 (ja) 2009-11-18
AU2003242305A8 (en) 2003-12-31
KR20050010913A (ko) 2005-01-28
KR101050703B1 (ko) 2011-07-20
DE60332355D1 (de) 2010-06-10
HK1083866A1 (en) 2006-07-14
EP1536009A4 (de) 2006-06-07
CN1675362A (zh) 2005-09-28
AU2003242305A1 (en) 2003-12-31
CN100408683C (zh) 2008-08-06
US20070082860A1 (en) 2007-04-12
EP1536009A1 (de) 2005-06-01
US7420034B2 (en) 2008-09-02
EP1536009B1 (de) 2010-04-28
CA2489227C (en) 2012-03-13
CN101113163A (zh) 2008-01-30
US7666985B2 (en) 2010-02-23
CA2489227A1 (en) 2003-12-24
WO2003106682A1 (ja) 2003-12-24

Similar Documents

Publication Publication Date Title
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
PL1731605T3 (pl) Nowotworowe peptydy antygenowe pochodzące z WT1
EP2228072A4 (de) Krebsimpfstoff-zusammensetzung
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
CY1119285T1 (el) Φορεις εμβολιου αδενοϊου χιμπατζη
DK1419154T3 (da) Rapamycin-29-enoler
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
NO20053999D0 (no) Survivin-avledede peptider og bruken av dem
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DK1871391T3 (da) Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE602006015837D1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
UY26170A1 (es) Antigeno (c42) asociados a tumores
WO2019147979A3 (en) Peptides for angiogenic therapy
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties